In the life sciences and diagnostics industry, software plays a crucial role in facilitating research, diagnostics, and patient care. However, software must meet different standards and regulations depending on its intended use. In this article, we will focus on software used in diagnostic settings and explore the key differences between In Vitro Diagnostic (IVD) software and Research Use Only (RUO) software. These differences go beyond technical aspects, extending to regulatory requirements, intended applications, development processes, and post-market obligations.
Understanding these distinctions is vital for laboratories, manufacturers, and software developers. This article explores the core differences between IVD and RUO software, shedding light on how each serves its purpose within the life sciences ecosystem.
Intended use and purpose
The primary distinction between IVD and RUO software lies in their intended use:
IVD Software: IVD software is designed for use in clinical settings to diagnose, prevent, or monitor diseases from patient samples from the human body. It directly influences patient treatment care by providing critical data used in medical decision-making. Because of its clinical application, IVD software must meet stringent regulatory standards to ensure safety, accuracy, and reliability.
RUO Software: RUO software is intended for use only in research settings. It explores scientific hypotheses, develops new assays, or conducts exploratory studies. RUO software is not intended to be used for clinical diagnosis or patient management. Consequently, it is generally not subject to the same level of regulatory scrutiny as IVD software. However, users must be aware that RUO software should not be used for patient-related purposes, as it may lack the validation and safeguards required for clinical use.
Regulatory requirements
One of the most significant differences between IVD and RUO software is the regulatory landscape:
IVD Software: IVD software is heavily regulated by health authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national regulatory bodies. In the EU, IVD software must comply with the In Vitro Diagnostic Regulation (IVDR), which outlines strict requirements for software safety, performance, and compliance. In the U.S., IVD software is regulated under the FDA’s 21 CFR Part 800 to 898 (especially parts 809, 820, 862, and 866) and must undergo rigorous validation and verification processes. These regulations ensure that IVD software is safe and effective for its intended clinical use, providing reliable results when analyzing data related to the human body, which healthcare professionals can trust.
RUO Software: RUO software is not intended for clinical diagnostics and, therefore, is not subject to the same regulatory requirements as IVD software. While RUO software may still need to comply with certain principles, processes, and methodologies, such as good software development practices, it does not require formal regulatory clearance or approval. Manufacturers typically label RUO software with disclaimers indicating that it is “for research use only” and “not for use in diagnostic procedures.” This distinction clarifies that RUO software has not been validated for clinical applications.
Development and validation
The development and validation processes for IVD and RUO software differ due to their varying regulatory requirements and intended uses:
IVD Software Development: IVD software development follows a highly structured process, including rigorous risk management, validation, and verification. Developers must identify potential risks, implement risk controls, and ensure the software meets all safety and performance criteria. Validation involves extensive testing in real-world clinical scenarios to demonstrate that the software produces accurate and reliable results. This process includes user acceptance testing, clinical performance studies, and compliance with standards such as ISO 13485 and IEC 62304. The goal is to ensure that the software functions correctly in a clinical environment and meets regulatory expectations. Since validation for IVD software requires extensive effort, the software updates tend to be less frequent than in RUO software.
RUO Software Development: While still requiring a methodical approach, RUO software development typically involves fewer regulatory constraints. The focus is on providing researchers with tools to explore scientific questions rather than producing validated diagnostic results. The validation process for RUO software is less intensive, often involving laboratory testing and functional verification rather than comprehensive clinical validation. While RUO software should be robust and reliable for research purposes, it does not need to meet the stringent performance standards required for IVD software.
Documentation and labeling
Documentation and labeling play crucial roles in differentiating IVD and RUO software:
IVD Software Documentation and Labelling: IVD software requires comprehensive documentation to demonstrate compliance with regulatory requirements. This includes detailed design specifications, risk assessments, validation reports, and user manuals. The labeling of IVD software must clearly state its intended use, instructions for use, and any limitations. It often includes specific regulatory markings, such as the CE mark in the EU, indicating that the software complies with relevant regulations and can be used for diagnostic purposes.
RUO Software Documentation and Labelling: RUO software documentation is generally less extensive, focusing on the software’s functionality and performance in research settings. The labeling for RUO software must explicitly state that it is for research use only and not intended for diagnostic procedures. This disclaimer is crucial to prevent the misuse of RUO software in clinical decision-making. Although RUO software documentation may not be as comprehensive as IVD documentation, it should still provide sufficient information for researchers to understand the software’s capabilities and limitations.
Post-market obligations
IVD and RUO software have different post-market obligations due to their varying regulatory statuses:
IVD Software Post-Market Obligations: Once IVD software is released, manufacturers are responsible for ongoing post-market surveillance to ensure the software continues to operate safely and effectively. This includes monitoring for adverse events, conducting periodic reviews, and implementing necessary updates or corrective actions. Post-market surveillance can be done through the manual gathering of user feedback or by streamlining that using telematics and user behavior analytics. Feasibility studies may also be conducted to assess the software’s performance in real-world clinical settings, ensuring it meets regulatory expectations and user needs. Regulatory authorities may require periodic reporting and audits to ensure continued compliance with regulatory standards. Post-market obligations help maintain the software’s performance and safety throughout its lifecycle.
RUO Software Post-Market Obligations: RUO software does not have the same level of post-market obligations as IVD software since it is not used in clinical diagnostics. However, developers of RUO software should still monitor performance and provide updates to address any issues or enhance functionality. While there are no formal post-market surveillance requirements for RUO software, maintaining software quality and reliability is important to support research activities effectively.
Transitioning from RUO to IVD
Some software products may initially be developed as RUO but later transition to IVD. This transition involves significant changes in development, validation, and regulatory compliance:
Regulatory Reclassification: Transitioning RUO software to IVD status requires regulatory reclassification. The software must undergo the necessary validation and verification processes to meet IVD requirements, including clinical validation and risk management. This often involves submitting the software for review by regulatory authorities, such as the FDA guidance or EMA, to obtain the required clearance or approval for clinical use.
Enhanced Validation: Transitioning from RUO to IVD necessitates enhanced validation, including extensive testing in clinical environments to ensure the software provides accurate, reliable, and reproducible results for diagnostic purposes. The software must be rigorously assessed for safety, effectiveness, and compliance with applicable regulatory standards.
Conclusion
The differences between IVD and RUO software are rooted in their intended use, regulatory requirements, development processes, extent of required documentation, and post-market obligations. IVD software plays a critical role in clinical diagnostics and is a subject to stringent regulations and validation to ensure it is safe and effective for clinical use. In contrast, RUO software is designed for exploratory research without the same level of regulatory oversight.
Understanding these distinctions is crucial for developers, manufacturers, and users to ensure that software is used appropriately and meets the necessary standards for its intended application. Whether for clinical diagnostics or research exploration, both IVD and RUO software play vital roles in advancing science and healthcare.
Watch our webinar: “How to Increase Efficiency in IVD Software Development,” for more insights on transitioning from RUO to IVD.
Discover practical insights on use cases, project development approaches, and tips for managing simultaneous RUO and IVD software development.
